Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant 20 mg in abdominally obese patients with dyslipidemia
2006-001715-30Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Abdominal adiposity (ABCD) and dyslipidemia comparing Rimonabant 20 mg with Placebo (2 arms). Primary endpoint: Co-primary endpoints: change in HDL cholesterol and triglycerides over 12 months. Started Aug 2006; status: terminated.
02
Drugs
rimonabant
03
Conditions
Abdominal adiposity (ABCD)dyslipidemia
Beyond the preview
Go deeper on 2006-001715-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001715-30.